Multiple Myeloma | China In-Depth | China | 2021
Multiple myeloma is an incurable hematological malignancy with a 100% mortality rate that affects a sizable portion of the Chinese population every year. With the introduction of proteasome inhibitors and immunomodulatory agents in China, the median overall survival has seen much improvement over the last decade. The multiple myeloma market of China is expected to expand further over the 2020-2030 period, fueled by the increasing disease incidence and an increasing uptake of targeted agents—most notably that of the recently launched daratumumab and upcoming carfilzomib, selinexor and isatuximab—owing to their potential efficacy in improving the progression-free survival (PFS) in patients, especially in the relapsed / refractory setting. Despite the availability of several traditional and novel agents over the forecast period, high unmet need will remain for therapies that can significantly improve patients’ PFS and overall survival (OS), representing an opportunity for new drug developers. Additionally, with the ongoing reforms in China’s regulatory and access and reimbursement landscape, multinational companies are likely to be increasingly incentivized to enter the multiple myeloma market of China.
QUESTIONS ANSWERED
- How large is China’s drug-treatable multiple myeloma population, and how will drug-treatment rates change during the forecast period?·
- Which are the most commercially relevant drugs in China’s multiple myeloma market and why? What are interviewed experts’ insights into current treatment options?·
- What are the market access considerations for key therapies in the multiple myeloma pipeline in China? What sales could these agents secure in multiple myeloma? What are interviewed experts’ opinions of key emerging therapies?·
- What are the key drivers and constraints in China’s multiple myeloma therapy market, and how will the market evolve over the forecast period?
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Release date
December 2021
Geographies
China
Primary Research
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 75 surveys with hematologist-oncologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology
Diagnosed incidence of multiple myeloma in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations
FORECAST
Annualized, 10-year, drug-level sales and patient share of key multiple myeloma therapies through 2030, based on primary and secondary market research to formulate bottom-up assumptions.
EMERGING THERAPIES
Phase III / PR: 7 drugs; Phase II: 5 drugs; coverage of select Phase I products.
